188P Impact of metformin, statin, aspirin and insulin on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab

M. Rimini; Elisabeth Amadeo; Francesco Vitiello; Silvia Foti; M. Persano; Toshifumi Tada; Goki Suda; S. Shimose; Masatoshi Kudo; Jaekyung Cheon; F. Finkelmeier; Ho Yeong Lim; F. Piscaglia; Gianluca Masi; Changhoon Yoo; S. Lonardi; Federico Rossari; Silvia Camera; A. Casadei Gardini; José Presa

doi:10.1016/j.annonc.2023.10.767

Preprint2024

Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab

Margherita Rimini, Margarida Montes, Elisabeth Amadeo, Francesco Vitiello, Masatoshi Kudo, Toshifumi Tada, Goki Suda, Shigeo Shimose, Sara Lonardi, Fabian Finkelmeier, Francesca Salani, Lorenzo Antonuzzo, Fabio Marra, Massimo Iavarone, Giuseppe Cabibbo, Francesco Giuseppe Foschi, Marianna Silletta, Rodolfo Sacco, Ilario Giovanni Rapposelli, Mario Scartozzi, P Nicoletta, Luca Aldrighetti, Mara Persano, Silvia Camera, Federico Rossari, Silvia Foti, Takashi Kumada, Atsushi Hiraoka, Hideki Iwamoto, Mario Domenico Rizzato, Vera Himmelsbach, Gianluca Masi, Mattia Corradi, Ciro Celsa, Fabio Conti, Giovanni Luca Frassineti, Stefano Cascinu, Andrea Casadei‐Gardini, José Presa

Article2024

Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab

Margherita Rimini, Margarida Montes, Elisabeth Amadeo, Francesco Vitiello, Masatoshi Kudo, Toshifumi Tada, Goki Suda, Shigeo Shimose, Sara Lonardi, Fabian Finkelmeier, Francesca Salani, Lorenzo Antonuzzo, Fabio Marra, Massimo Iavarone, Giuseppe Cabibbo, Francesco Giuseppe Foschi, Marianna Silletta, Rodolfo Sacco, Ilario Giovanni Rapposelli, Mario Scartozzi, P Nicoletta, Luca Aldrighetti,

Article2023

165P BMI impact on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab

Elisabeth Amadeo, M. Persano, Toshifumi Tada, Goki Suda, S. Shimose, Masatoshi Kudo, Changhoon Yoo, Federico Rossari, Francesco Vitiello, A. Casadei Gardini, M. Rimini

Article2024

Impact of body mass index on the prognosis of unresectable HCC patients receiving first‐line Lenvatinib or atezolizumab plus bevacizumab

Margherita Rimini, Bernardo Stefanini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Fabian Finkelmeier, Changhoon Yoo, José Presa, Elisabeth Amadeo, V. Genovesi, Maria Caterina De Grandis, Massimo Iavarone, Fabio Marra, Francesco Giuseppe Foschi, Emiliano Tamburini, Federico Rossari, Francesco Vitiello, L. Bartalini, Caterina Soldà, Francesco Tovoli, Caterina Vivaldi,

Article2022

Does first‐line treatment have prognostic impact for unresectable <scp>HCC</scp>?—Atezolizumab plus bevacizumab versus lenvatinib

Atsushi Hiraoka, Takashi Kumada, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Atsushi Naganuma, ,

188P Impact of metformin, statin, aspirin and insulin on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab

Discussion(0)

Related publications

Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab

Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab

165P BMI impact on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab

Impact of body mass index on the prognosis of unresectable HCC patients receiving first‐line Lenvatinib or atezolizumab plus bevacizumab

Does first‐line treatment have prognostic impact for unresectable <scp>HCC</scp>?—Atezolizumab plus bevacizumab versus lenvatinib